- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07342608
Sicherheit und Leistung der LINEA Herzschrittmachersonde, optimiert für die Implantation im Kammerseptum (STARLIGHT)
Sicherheit und Leistung des LINEA Herzschrittmacher-Elektrodenkabels optimiert für die Implantation im Interventrikularseptum
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Antoine Guihard
- Telefonnummer: +33 1 46 01 33 20
- E-Mail: antoine.guihard@cf.microport.com
Studienorte
-
-
-
Ghent, Belgien
- Rekrutierung
- Ghent University Hospital
-
Kontakt:
- Jan De Pooter
- E-Mail: jadpoote.depooter@ugent.be
-
-
-
-
-
Annecy, Frankreich
- Rekrutierung
- Centre Hospitalier Annecy Genevois
-
Kontakt:
- Pierre Frey
- E-Mail: pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand, Frankreich
- Rekrutierung
- CHU Clermont-Ferrand
-
Kontakt:
- Pierre-Antoine Catalan
- E-Mail: pacatalan@chu-clermontferrand.fr
-
Grenoble, Frankreich
- Rekrutierung
- CHU Grenoble
-
Kontakt:
- Adrien Carabelli
- E-Mail: acarabelli@chu-grenoble.fr
-
Montpellier, Frankreich
- Rekrutierung
- Clinique du Millénaire
-
Kontakt:
- Nicolas Clémenty
- E-Mail: nicolas.clementy@gmail.com
-
Rouen, Frankreich
- Rekrutierung
- CHU Rouen Hôpital Charles Nicolle
-
Kontakt:
- Raphaël Al Hamoud
- E-Mail: raphael.al-hamoud@chu-rouen.fr
-
Tours, Frankreich
- Rekrutierung
- Hôpital Trousseau
-
Kontakt:
- Arnaud Bisson
- E-Mail: a.bisson@chu-tours.fr
-
-
-
-
-
Novara, Italien
- Rekrutierung
- Ospedale Maggiore della Carità - AO Univ.
-
Kontakt:
- Gabriele Dell'Era
- E-Mail: gabriele.dellera@maggioreosp.novara.it
-
Pisa, Italien
- Rekrutierung
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
Kontakt:
- Gianluca Mirizzi
- E-Mail: gmirizzi@ftgm.it
-
-
-
-
-
Coimbra, Portugal
- Rekrutierung
- ULS de Coimbra
-
Kontakt:
- João Ferreira
- E-Mail: joaoaferreira29@gmail.com
-
Lisbon, Portugal
- Rekrutierung
- ULS Santa Maria
-
Kontakt:
- Nelson Cunha
- E-Mail: nelsoncunha@campus.ul.pt
-
-
-
-
-
Girona, Spanien
- Rekrutierung
- Hospital Universitari de Girona Doctor Josep Trueta
-
Kontakt:
- María Emilce Trucco
- E-Mail: metrucco.girona.ics@gencat.cat
-
Granada, Spanien
- Rekrutierung
- Hospital Universitario Virgen de las Nieves
-
Kontakt:
- Manuel Molina
- E-Mail: manuel.molina.lerma@gmail.com
-
Valencia, Spanien
- Rekrutierung
- Hospital Universitari i Politècnic La Fe
-
Kontakt:
- Óscar Cano
- E-Mail: oscape13@hotmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: LINEA Herzschrittmacher-Elektrode
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
LINEA lead complication free rate at 3 months
Zeitfenster: 3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
Zeitfenster: 3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
Zeitfenster: 3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
Zeitfenster: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
Zeitfenster: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Zeitfenster: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
Zeitfenster: Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
Zeitfenster: Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Zeitfenster: Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
Zeitfenster: 3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
Zeitfenster: 18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Zeitfenster: 1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Zeitfenster: 1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Zeitfenster: 1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Zeitfenster: 1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Zeitfenster: 1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- LLAI01 - STARLIGHT
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .